Product
NMS-03592088
1 clinical trial
2 indications
Indication
Acute Myeloid LeukemiaIndication
Chronic Myelomonocytic LeukemiaClinical trial
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMMLStatus: Recruiting, Estimated PCD: 2025-12-28